Short answer
Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Item 2.02 covers Entrada Therapeutics’ May 7, 2026 financial results disclosure.
Entrada Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 covers Entrada Therapeutics’ May 7, 2026 financial results disclosure
- Investors should review Exhibits 99.1 and 99.2 for earnings figures, financial condition, and management commentary
- CEO Dipal Doshi signed the filing on May 7, 2026
Item 7.01 · Regulation FD Disclosure
- Positive topline results from Cohort 1 of ENTR-601-44 Phase 1/2 ELEVATE-44-201 study
- Duchenne muscular dystrophy program update, potentially advancing clinical development and investor expectations
- Press release issued May 7, 2026; detailed efficacy and safety results in Exhibit 99.2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Entrada Therapeutics, Inc. 8-K filings
Get the next TRDA 8-K as it lands
Follow TRDA for push alerts, or ask the research agent what this filing means.